Skip to main content
SEPN
NASDAQ Life Sciences

Septerna 10-Q: Q3 Revenue $18.9M, Net Loss $26.6M, $565.2M Cash Into Mid-2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$50.74
Mkt Cap
$2.368B
52W Low
$17.55
52W High
$51.1
52W Position info
189% above low
Off High info
at 52W high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

SEPN has more than doubled off its 52-week low of $17.55.

Summary

Septerna's Q3 10-Q confirms $18.9M revenue and a $26.6M net loss, with R&D up sharply and $565.2M in cash funding operations into mid-2029. The filing also discloses $61.0M of Q3 ATM sales and a dropped Phase 2b plan for SEP-631.


Key Events · Earnings and Guidance · SEPN

  • Q3 Revenue $18.9M, Net Loss $26.6M

    Revenue fell to $18.9M from $21.5M a year earlier, and the quarter swung to a $26.6M net loss from $8.2M of net income in Q3 2025.

  • R&D Spend Steps Up Sharply

    Research and development rose to $36.6M from $24.3M, with higher costs across PTH1R, partnered metabolic and other preclinical programs plus $3.0M more payroll.

  • Novo Contract Modification Cuts Revenue

    Novo's program substitution triggered a contract modification and a $13.2M cumulative catch-up reduction to revenue in the quarter.

  • Cash of $565.2M Into Mid-2029

    Cash, cash equivalents and marketable securities totaled $565.2M at September 30, 2026, which the company says funds operations at least into mid-2029.


Analysis · SEPN · Life Sciences

The headline numbers were already out via the same-day 8-K, but the full 10-Q shows what is actually happening underneath. R&D jumped to $36.6M from $24.3M a year earlier as SEP-479 and SEP-204 move toward the clinic, and a $13.2M cumulative catch-up cut to revenue from the Novo contract modification dragged the top line. Against that, $565.2M of cash and securities funds operations into mid-2029, so there is no near-term financing pressure — and the company raised $61.0M net through the ATM in Q3 at a $39.43 weighted average, well below today's $50.74. The quiet negative is SEP-631: the planned Phase 2b CSU trial is off the table in favor of unspecified signal-finding work.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SEPN was trading at $50.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $17.55 to $51.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SEPN - Latest Insights

SEPN
Nov 09, 2026, 4:03 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.74
Real-time Price: $48.56 info
Change: -$2.18 (-4%) info
Market Cap: $2.309B info
SEPN
Nov 04, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $43.70
Real-time Price: $48.56 info
Change: +$4.86 (+11%) info
Market Cap: $2.309B info
SEPN
Aug 14, 2026, 5:14 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $45.39
Real-time Price: $48.56 info
Change: +$3.17 (+7%) info
Market Cap: $2.309B info
SEPN
Aug 12, 2026, 6:55 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $48.19
Real-time Price: $48.56 info
Change: +$0.370 (+0.77%) info
Market Cap: $2.309B info
SEPN
Jun 22, 2026, 4:16 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $34.85
Real-time Price: $48.56 info
Change: +$13.71 (+39%) info
Market Cap: $2.309B info